In clinical studies and real-world use, Basal-IQ technology reduced the frequency and duration of lows.
Use of the t:slim X2™ insulin pump with Basal-IQ™ technology in a six-week PLGS (Predictive Low Glucose Suspend) for Reduction of Low Glucose (PROLOG) Study (n=102) demonstrated a 31% reduction in time spent below 3.9 mmol/L compared to a sensor-augmented pump (SAP).1 Real-world use of Basal-IQ technology (n=2,712) has demonstrated even greater reductions in time spent low.2
Learn more about THE Real-World Study
Data on real-world use of Basal-IQ technology in Diabetes Technology & Therapeutics >
Time Spent < 3.9 mmol/L (%)
Help for people who can’t recognize when they’re going low.
Basal-IQ predictive low-glucose suspend technology is a simple-to-use system that predicts and helps prevent lows. In the PROLOG pivotal study, the reduction of time spent in low glucose was accomplished without any increase in the rate of hyperglycemia.1
How does Basal-IQ technology work?
Basal-IQ technology uses a simple, linear regression algorithm that uses Dexcom G6 CGM values to predict glucose levels 30 minutes ahead based on three of the last four consecutive CGM readings. If the glucose level is predicted to be fewer than 4.4 mmol/L, or if a CGM reading falls below 3.9 mmol/L, insulin delivery is suspended. Insulin delivery resumes as soon as sensor glucose values begin to rise. Insulin may be suspended for a minimum of five minutes and a maximum of two hours within a 2.5-hour rolling window.
Technology that’s simple to teach and learn can help reduce the training burden on healthcare professionals.
Zero Fingersticks
When the t:slim X2 pump is integrated with Dexcom G6 CGM, zero fingersticks are required for calibration or mealtime dosing.*
Easy to Use
97% of study participants felt very confident using the Basal-IQ feature on the t:slim X2 insulin pump.1
Responsive Insulin Delivery
Basal-IQ technology can turn insulin delivery on and off as often as every five minutes. There is no minimum insulin suspension period. Insulin resumes as soon as sensor glucose values begin to rise.
No Refractory Period
There is no refractory period during which the feature is unavailable. Basal-IQ technology can suspend insulin for up to two hours within a 2.5‑hour rolling window.
Operates Silently in the Background
No added alerts or alarms beyond standard CGM and pump notifications.† Users must only decide whether they want the Basal-IQ technology feature on their t:slim X2 insulin pump turned on or off.
*Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 continuous glucose monitoring (CGM) integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter
to make diabetes treatment decisions.
Responsible Use of Basal-IQ Technology
* Zero fingersticks required when using the t:slim X2 pump with Dexcom G6 continuous glucose monitoring (CGM) integration. If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
† Users have the option to request alerts when insulin is suspended and when it resumes. Patients will receive standard CGM alerts and alarms related to low glucose levels that require attention.
References:
1. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG
trial. Diabetes Care. 2018;41(10):2155-2161.
2. Beck RW, et al. The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. Diabetes Technol Ther.2019;21(1):1-5.
Important Safety Information
The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the System can be used to suspend insulin delivery based on CGM sensor readings. The pump and the System are indicated for use in individuals six years of age and greater. The pump and the System are intended for single user use. The pump and the System are indicated for use with NovoRapid, Admelog, or Humalog U-100 insulin. The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.